Photodynamic Therapy for Barrett's Esophagus and Esophageal Carcinoma

Qumseya, Bashar J.; David, Waseem; Wolfsen, Herbert C.

doi:10.5946/ce.2013.46.1.30

Cited by 70 publications

(51 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This generates various cytotoxic reactive oxygen species such as singlet oxygen that can interact with and damage cellular components, leading to cell death. Many photosensitisers have been developed and have received approval or clinical trials for use in the treatment of cancer, 2 age-related macular degeneration, 3 pre-cancerous conditions such as Barret's oesphagus, 4 and oral sterilisation in dental procedures. 5 Among these, porphyrins and other tetrapyrrole-related compounds remain the broadest class of compound under study for PDT and other light-based therapies.…”

Section: Introductionmentioning

confidence: 99%

Flexible synthesis of cationic peptide–porphyrin derivatives for light-triggered drug delivery and photodynamic therapy

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Flexible synthesis of cationic peptide–porphyrin derivatives for light-triggered drug delivery and photodynamic therapy

et al. 2016

View full text Add to dashboard Cite

show abstract

“…PDT has clinical applications in the treatment of a variety of solid cancers [4,[7][8][9][10][11][12][13][14][15][16][17][18][19][20][21], including but not limited to those of lung, skin, breast, head and neck, digestive tract, pancreas, liver, bladder, ovary, prostate and brain. In addition, there are many clinical applications of PDT for treatment of a wide range of non-cancerous conditions, such as bacterial and fungal infections; hyperproliferative or inflammatory conditions, such as macular degeneration or psoriasis; and premalignant conditions, such as actinic keratosis [22] and Barrett's esophagus [23]. To achieve better therapeutic efficacy, new photosensitizers and novel light sources are continuously being developed, and the mechanisms of action are becoming better understood [24,25].…”

mentioning

confidence: 99%

Photodynamic Therapy as an Emerging Treatment Modality for Cancer and Non-Cancer Diseases

Hu¹

2014

J Anal Bioanal Tech

View full text Add to dashboard Cite

Hu et al., J Anal Bioanal Tech 2014, S1 http://dx.doi.org/10.4172/2155-9872.S1-e001 ISSN: 2155-9872 JABT, an open access journal Photodynamic Therapy-Cancer J Anal Bioanal TechPhotodynamic therapy (PDT) is a treatment modality involving photoactivatable chemicals (called photosensitizers), light and tissue oxygen [1][2][3][4][5][6]. PDT has clinical applications in the treatment of a variety of solid cancers [4,7-21], including but not limited to those of lung, skin, breast, head and neck, digestive tract, pancreas, liver, bladder, ovary, prostate and brain. In addition, there are many clinical applications of PDT for treatment of a wide range of non-cancerous conditions, such as bacterial and fungal infections; hyperproliferative or inflammatory conditions, such as macular degeneration or psoriasis; and premalignant conditions, such as actinic keratosis [22] and Barrett's esophagus [23]. To achieve better therapeutic efficacy, new photosensitizers and novel light sources are continuously being developed, and the mechanisms of action are becoming better understood [24,25]. To achieve improved tumor selectivity and to reduce side effects in the treatment of cancer, the concept of targeted photodynamic therapy has been successfully developed by attaching specific functionalities to the photosensitizer, such as antibodies recognizing tumor antigens [26,27], or ligands and peptides to recognize receptors [28], which could be selectively expressed on one of the two major tumor compartments, either on the malignant cells or on tumor neovasculature. To achieve better efficacy than PDT that is targeted to a single tumor compartment (stPDT), a recent editorial [29] in this Journal summarized a new PDT approach (Figure 1), which was designed for dual targeting of photosensitizers (dtPDT) to both malignant cells and neovasculature [30,31] by conjugating photosensitizers to a protein, factor VII, the natural ligand for tissue factor. This approach allows for dual targeting of malignant cells and of tumor neovasculature, both of which either overexpress or selectively express tissue factor [30][31][32][33], respectively.In this special issue on PDT-Cancer, PDT scientists and experts worldwide contributed seven peer-reviewed articles. These review and research articles broadly cover the use and applications of PDT for cancer, for infections and for inflammatory conditions. Menon and Stafinski [34] in Canada thoroughly reviewed reports of clinical applications and clinical trials of PDT for the treatment of different types of cancers that were published in English between January 1997 and June 2011. They summarized a total of 266 studies, which involved 11,427 patients and 34 different types of cancer in diverse organs, such as anal and perianal cutaneous cancers, as well as cancers of the bile duct, bladder, brain, breast, cervical, esophageal, eye, gastrointestinal, head and neck, lung, peritoneal cavity, colorectal, liver, ovary, pancreas, prostate, skin, vulva, etc. Tsipursky, Churgin, Conway and Peyman [35] in the Uni...

show abstract

“…12 WST11-VTP differs from classical PDT 20-26 and offers major advantages, including absence of prolonged skin photosensitivity, which has been a major barrier to widespread utilization of traditional PDT. 22-24 WST11-VTP has been successfully and safely applied in phase II clinical trials for tissue ablation in cancer bearing organs. 14,15 Results from studies In prostate cancer have shown well-preserved quality of life, indicating the potential to overcome the disadvantages of other ablation approaches.…”

Section: Discussionmentioning

confidence: 99%

Treatment Effects of WST11 Vascular Targeted Photodynamic Therapy for Urothelial Cell Carcinoma in Swine

et al. 2016

View full text Add to dashboard Cite

Purpose Surgical management of upper tract urothelial carcinoma requires removal of kidney and ureter, compromising renal function. Non-surgical alternatives have potentially prohibitive safety concerns. We examine the feasibility and safety of ablation of the ureter and renal pelvis using endoluminal vascular-targeted photodynamic therapy in a porcine model and report efficacy of WST11 vascular-targeted photodynamic therapy in a murine model. Materials and Methods Following approval, we performed 28 endoluminal ablations in the ureters and renal pelvis of 18 swine. Intravenous infusion of WST11 (4mg/kg) followed by laser illumination (10 minutes) was performed via percutaneous access or retrograde ureteroscopic approach. Animals were followed clinically with laboratory testing, imaging and histology was evaluated at several post-ablation time points. A murine xenograft was created with the 5637 human urothelial cell carcinoma line to determine sensitivity to this therapy. Results At 24 hours, 50 mW/cm laser fluence produced superficial necrosis of the ureter and deeper necrosis (penetrating the muscularis propria or adventitia) was produced by treatment with 200 mW/cm in the ureter and renal pelvis. At 4 weeks, superficial urothelium had regenerated over the treatment site. No symptomatic obstruction, clinically relevant hydronephrosis, or abnormality of lab testing was noted up to 4 weeks. In mice, 80% had no evidence of tumor at 19 days after WST11 vascular-targeted photodynamic therapy. Conclusions Urothelial cell carcinoma appears to be sensitive to WST11 vascular-targeted photodynamic therapy. Depth of WST11 vascular-targeted photodynamic therapy treatment effects can be modulated in a dose-dependent manner by titration of light intensity. Moreover, this treatment modality, applied to the porcine upper urinary tract, is feasible via antegrade and retrograde access.

show abstract

Photodynamic Therapy for Barrett's Esophagus and Esophageal Carcinoma

Abstract: This paper reviews the use of photodynamic therapy (PDT) in patients with Barrett's esophagus and esophageal carcinoma. We describe the history of PDT, mechanics, photosensitizers for PDT in patients with esophageal disease. Finally, we discuss its utility and limitations in this setting.

Cited by 70 publications

References 88 publications

Flexible synthesis of cationic peptide–porphyrin derivatives for light-triggered drug delivery and photodynamic therapy

Flexible synthesis of cationic peptide–porphyrin derivatives for light-triggered drug delivery and photodynamic therapy

Photodynamic Therapy as an Emerging Treatment Modality for Cancer and Non-Cancer Diseases

Treatment Effects of WST11 Vascular Targeted Photodynamic Therapy for Urothelial Cell Carcinoma in Swine

Contact Info

Product

Resources

About